Safety and Efficacy of SPARC1203 in Allergic Rhinitis

• Status: Completed
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess safety and efficacy of SPARC1203 delivered via nasal spray in patients with allergic rhinitis

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Pharma Advanced Research Company Limited

Criteria

Inclusion Criteria:

• Male and female patients aged 18 to 65 years (both inclusive) with history of seasonal allergic rhinitis and positive skin prick test

Exclusion Criteria:

• History or presence of perennial allergic rhinitis

• Upper or lower respiratory tract infection 2 weeks before Visit 2

• Significant pulmonary disease other than allergic rhinitis or mild asthma controlled by beta-2-agonists alone

• Immunizations or vaccinations within 4 weeks prior to Visit 1